Christian J Bachmann1, Alexandra Philipsen, Falk Hoffmann. 1. Faculty of Medicine, Philipps-Universität Marburg; Faculty of Medicine and Health Sciences, Carl von Ossietzky Universität Oldenburg, Department of Psychiatry and Psychotherapy, Karl-Jaspers Hospital, Bad Zwischenahn; Faculty of Medicine and Health Sciences, Carl von Ossietzky Universität Oldenburg, Department of Health Services Research.
Abstract
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) sometimes persists into adulthood. There have been no studies from Germany until the present time on the diagnosis and treatment of ADHD over the course of patients' lives, in particular during the transition from adolescence to early adulthood. METHODS: We used nationwide routine data of the AOK statutory healthinsurance fund to determine the frequency of ADHD diagnoses and prescriptions of medication for ADHD. We additionally analyzed the care of a transition cohort of initially 15-year-old ADHD patients over a period of six years. RESULTS: From 2009 to 2014, the prevalence of a diagnosis of ADHD rose from 5.0% to 6.1% in persons aged 0 to 17 years (with a maximum of 13.9% in 9-year-old boys) and from 0.2% to 0.4% in persons aged 18 to 69 years. The amount of ADHD medication prescribed to adults with ADHD increased over time, while the amount prescribed to children and adolescents fell. Methylphenidate was the most commonly prescribed drug, followed by atomoxetine and lisdexamfetamine. Only 31.2% of the patients in the transition cohort still carried the diagnosis of ADHD at the end of the six-year period, at age 21. The percentage of patients taking ADHD medication in this group fell from 51.8% at age 15 to 6.6% at age 21. CONCLUSION: The administrative prevalence of a diagnosis of ADHD among adults and the degree of medication use for ADHD by adults have risen in recent years. This can be interpreted as an indication of the sensitization of physicians and patients to the possibility of adult ADHD. Nonetheless, the prevalence of diagnosed ADHD remains less than the prevalence revealed by epidemiologic studies. This may indicate that adults with ADHD are currently underdiagnosed and undertreated. The low rate of use of ADHD medications among adolescents with ADHD who are on the verge of adulthood leads us to the question of whether specific transitional concepts need to be developed for this age group.
BACKGROUND:Attention-deficit/hyperactivity disorder (ADHD) sometimes persists into adulthood. There have been no studies from Germany until the present time on the diagnosis and treatment of ADHD over the course of patients' lives, in particular during the transition from adolescence to early adulthood. METHODS: We used nationwide routine data of the AOK statutory healthinsurance fund to determine the frequency of ADHD diagnoses and prescriptions of medication for ADHD. We additionally analyzed the care of a transition cohort of initially 15-year-old ADHDpatients over a period of six years. RESULTS: From 2009 to 2014, the prevalence of a diagnosis of ADHD rose from 5.0% to 6.1% in persons aged 0 to 17 years (with a maximum of 13.9% in 9-year-old boys) and from 0.2% to 0.4% in persons aged 18 to 69 years. The amount of ADHD medication prescribed to adults with ADHD increased over time, while the amount prescribed to children and adolescents fell. Methylphenidate was the most commonly prescribed drug, followed by atomoxetine and lisdexamfetamine. Only 31.2% of the patients in the transition cohort still carried the diagnosis of ADHD at the end of the six-year period, at age 21. The percentage of patients taking ADHD medication in this group fell from 51.8% at age 15 to 6.6% at age 21. CONCLUSION: The administrative prevalence of a diagnosis of ADHD among adults and the degree of medication use for ADHD by adults have risen in recent years. This can be interpreted as an indication of the sensitization of physicians and patients to the possibility of adult ADHD. Nonetheless, the prevalence of diagnosed ADHD remains less than the prevalence revealed by epidemiologic studies. This may indicate that adults with ADHD are currently underdiagnosed and undertreated. The low rate of use of ADHD medications among adolescents with ADHD who are on the verge of adulthood leads us to the question of whether specific transitional concepts need to be developed for this age group.
Authors: John Fayyad; Nancy A Sampson; Irving Hwang; Tomasz Adamowski; Sergio Aguilar-Gaxiola; Ali Al-Hamzawi; Laura H S G Andrade; Guilherme Borges; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Chiyi Hu; Elie G Karam; Sing Lee; Fernando Navarro-Mateu; Siobhan O'Neill; Beth-Ellen Pennell; Marina Piazza; José Posada-Villa; Margreet Ten Have; Yolanda Torres; Miguel Xavier; Alan M Zaslavsky; Ronald C Kessler Journal: Atten Defic Hyperact Disord Date: 2016-11-19
Authors: Holly E Erskine; Rosana E Norman; Alize J Ferrari; Gary C K Chan; William E Copeland; Harvey A Whiteford; James G Scott Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-08-04 Impact factor: 8.829
Authors: Alexandra Philipsen; Thomas Jans; Erika Graf; Swantje Matthies; Patricia Borel; Michael Colla; Laura Gentschow; Daina Langner; Christian Jacob; Silke Groß-Lesch; Esther Sobanski; Barbara Alm; Martina Schumacher-Stien; Michael Roesler; Wolfgang Retz; Petra Retz-Junginger; Bernhard Kis; Mona Abdel-Hamid; Viola Heinrich; Michael Huss; Catherine Kornmann; Arne Bürger; Evgeniy Perlov; Gabriele Ihorst; Michael Schlander; Mathias Berger; Ludger Tebartz van Elst Journal: JAMA Psychiatry Date: 2015-12 Impact factor: 21.596
Authors: Sarah Wolff; Kristin Queiser; Leonie Wessendorf; Anna Maria Meier; Moritz Verdenhalven; Oliver Grimm; Christoph Reimertz; Christoph Nau; Michelle Klos; Andreas Reif; Sarah Kittel-Schneider Journal: J Neural Transm (Vienna) Date: 2019-05-10 Impact factor: 3.575
Authors: Melanie Schubert; Janice Hegewald; Alice Freiberg; Karla Romero Starke; Franziska Augustin; Steffi G Riedel-Heller; Hajo Zeeb; Andreas Seidler Journal: Int J Environ Res Public Health Date: 2019-09-10 Impact factor: 3.390
Authors: Y Okumura; M Usami; T Okada; T Saito; H Negoro; N Tsujii; J Fujita; J Iida Journal: Epidemiol Psychiatr Sci Date: 2018-05-28 Impact factor: 6.892
Authors: Brian J Piper; Christy L Ogden; Olapeju M Simoyan; Daniel Y Chung; James F Caggiano; Stephanie D Nichols; Kenneth L McCall Journal: PLoS One Date: 2018-11-28 Impact factor: 3.240
Authors: Berit Libutzki; Melanie May; Markus Gleitz; Michael Karus; Benno Neukirch; Catharina A Hartman; Andreas Reif Journal: Eur Psychiatry Date: 2020-10-01 Impact factor: 5.361